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food supplements promising a short cut to weight con

PHLORETIN AND PHLORIZIN DERIVATIVE
CONTAINING COMPOUNDS

trol without dietary discipline. Despite the commercial
success of these starch blockers, however, there is no

evidence that these preparations actually inhibit starch

TECHNICAL FIELD

or calorie absorption in vivo. In fact, in a decisive study
with human volunteers, Fordran and his coworkers
showed no increase in calories lost in feces caused by

The present invention relates to innovative com

pounds having phloretin or phlorizin moieties and their
use as a new and novel class of clinically safe pharmaco

logical agents. More particularly, the present invention
relates to certain new phloretin and phlorizin derivative 10

containing compounds, pharmaceutical compositions

these amylase inhibitors (Bo-Linn, G. W., Santa Ava, C.
A., Morawski, S. G. and Fordran, J. S., New Engl. J.
Med. 307 (1982) 1413).
It is generally accepted that the transport system
responsible for the active renal reabsorption of D
glucose is localized in the luminal membrane or brush
border of proximal tubular cells (see Vick, Diedrich and
Baumann, Am. J. of PhysioL, Vol. 224, No. 3, March

thereof, their methods of preparation, and their meth
ods of use in inhibiting sugar uptake from the small
intestine for the treatment of diabetes, obesity and

dumping syndrome.

(1973) 552-557). Experimental evidence indicates that

BACKGROUND ART

the glucose interacts with a component or carrier of the
membrane that facilitates the entry of the sugar into the
cells. For example, the ?nal step in carbohydrate as
similiation by the small intestine has been shown to be

Current pharmacological therapy for the overweight
patient focuses on two approaches: appetite regulation
and modulation of intestinal absorption processes. The
?rst approach involves the administration of anoretic
agents, such as amphetamines, to the patient in order to
control caloric intake. Typically, the amphetamines are

the active absorption of enzyme generated mono-sac
charides via a Na+-dependent transporter in the epithe

lial brush border membranes.
Phlorizin is known to be a highly effective and spe
behaviorally designed weight reduction program. 25 ci?c
blocker of sugar absorption from the intestinal
While these agents are strong suppressors of appetite,
used as short term adjuncts to a nutritionally and/or

tract. In fact, studies have indicated that this naturally
occurring compound found in the bark and other com
ponents of apple and other fruit trees is a potent compet
The second approach to control body weight in 30 itive inhibitor of the sugar transport process having an
af?nity for the sugar transporter of about 1,000 times
volves the reduction of the availability of nutrients by
greater than D-glucose (Bode, F., Baumann, K., and
affecting digestion and/or absorption. The success of
Diedrich, D. F., Biochem. Biophys. Acta 290 (1972)
intestinal by-pass operations for the treatment of obesity
134). Phlorizin, however, is not a clinically useful and
has encouraged the search for oral agents which might

their systemic action is associated with dangerous cen
tral nervous system side effects and humeral/neuro
transmitter imbalances.

produce a chemically induced, reversible form of al 35 safe pharmacological agent that may be used in the
management of diabetic and obese patients.
tered intestinal absorption. A number of compounds
Orally administered phlorizin not only blocks the in
have been examined in studies designed to block the
vivo intestinal absorption of glucose in rats and dogs but
intestinal uptake of lipids. Such an approach, however,
it also causes a “phlorizin diabetes” or glucosuria. Some
disadvantageously causes essential lipid-soluble vitamin
of the phlorizin survives the hydrolytic environment of
malabsorption and other serious disorders (Dobbins, W.
the gastrointestinal tract, is absorbed intact, and is car
0., Herrero, B. A. and Mansbach, C. M., Am. J. Med.
ried to the kidneys where it blocks the sugar trans
Sci. 255 (1968) 63; Bray, G. A., “Drug Therapy for the
porter. Furthermore, as some of the phlorizin travels
Obese Patient” in The Obese Patient, (1976) p. 353, Saun
through the digestive system, it is hydrolyzed by the
ders, Philadelphia; and Evans, E., Miller, D. 8., Samuel,
P. D. and Burland, W. L., Postgrad. Med. J. 51, Suppl. 45 intestinal epithelia to phloretin (Diedrich, D. F., Arch.

Biochem. Biophys, 127 (1968) 803) which readily enters

1 (1975) 1204).

In order to avoid this problem, recent research has
the blood stream to cause at appropriate levels pro
found toxic effects at all sites in the body.
been directed toward the development of “starch block
ers”. An example of these is a preparation of amylase
While phlorizin is not a clinically useful and safe
inhibitors which are proposed to block carbohydrate 50 pharmacological agent, it is a valuable study tool. Tests

absorption (Keup, V. and Puls, W., Arch. Pharmacol.
297 Suppl. (1975) R85). The rationale for this approach

and studies of phlorizin have shown that the- glucose
moiety of phlorizin is an essential substituent of a potent

relies on the fact that the enzyme amylase, normally
sugar uptake inhibitor molecule. Experimental results
secreted in saliva and from the pancreas, hydrolyzes
bear out this postulate with regard to at least a part of
starch randomly to glucose and maltose. The maltose is 55 this moiety (Diedrich, D. F., “In vitro Evaluation of

then degraded by maltase to the mono-saccharide glu

Relative Inhibitory Potency of Phlorizin and its Conge
ners”, Am. J. PhysioL, Vol. 209, No. 3, September
(1965)). Clearly, however, since the af?nity for the

cose. The monosaccharides are the only form of any

dietary carbohydrate that is absorbed by intestinal
transport mechanisms. Thus, if the amylase is inhibited
from hydrolyzing the starch, intestinal absorption is

transport site by phlorizin is approximately 1,000 times
60

greater than that shown by glucose, some feature of the

blocked. Over 100 different varieties of these “starch

aglucone moiety of phlorizin facilitates the interaction

blocker” preparations have been placed on the market.
They are widely sold by pharmacies and health food

of the glucosidic portion of the molecule with the re
ceptor. As a result of the interaction, the stability of the

stores. The use of these “over-the-counter” offerings

phlorizin formed complex is much greater than that

has been so attractive that over a million tablets were 65 formed with the free sugar.

consumed daily in the United States during the first part
of 1982. These consumption ?gures indicate that the
public is remarkably responsive to claims for diet and

Further experiments with phlorizin and other struc
turally related glycosides have resulted in the identi?ca
tion of several features which describe the critical struc

3
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ture of a potent inhibitor of the absorption of glucose.
The inhibitory agent is one that possesses atomic group
ings in a speci?c three-dimensional pattern. The pattern
favors an association with the membrane receptor. The

4
R1

R

OH

OH

molecule is visualized to be bound at two or more loci. 5

and

A primary bond is formed through the interaction of the

II

glycosidic moiety with appropriate groups of the mem
brane constituent. The linkage presumably is formed
through hydrogen bonds that involve at least the hy

OH

O
OH

droxyl groups on G3 and C-4 of the sugar group. The
most stable primary interaction occurs when these hy
droxyl groups are situated in the more chemically reac

OH

tive equatorial position. A secondary bonding of the

O

aglucone portion of the inhibitor molecule to a locus on

the biological surface is adjacent to, but removed from
the plane of the glucose transporting site. The linkage is

15

HO
HO

probably through hydrogen bonding between the oxy
gen of the 4-hydroxyphenyl moiety and a membrane
constituent capable of serving as a hydrogen donor at

physiological pH. The locus is approximately 13-16 A
A removed from the transport site to which glucose is

normally bound.

O§
O

OH

OH

R1
20

wherein R is —OH or —H and R1 is a primary amine

moiety. Speci?c examples of intermediate compounds

used to form the complete compound of the invention
The present invention uses the information gained
include 4'-deoxyphlorizin-5'-benzylamine, phlorizin-5'
from the studies of the geometric con?guration and 25 benzylamine and phloretin-3'-benzylamine.
chemical structure of the inhibitory mechanism of
In accordance with the objects and advantages of the
phlorizin, phloretin and related derivatives and ad
present invention, compounds for inhibiting sugar up
vances the art by providing compounds and composi
take from the small intestine comprise a reaction prod
tions having pharmacological ef?cacies. Particularly
uct formed from serially coupling (1) an undigestible
the compounds act as pharmacological agents that are
and non-absorbable matrix with a leash forming com
clinically useful and safe in inhibiting sugar uptake with
pound to form a ?rst intermediate product; (2) the ?rst
out systemic side effects.
intermediate product with an intermediate phloretin or
phlorizin derivative (as de?ned above) to form a second
SUMMARY OF THE INVENTION

Accordingly, it is a primary object of the present
invention to provide innovative and novel compounds
having phloretin or phlorizin moieties and pharmaco

intermediate product; and (3) the second intermediate

35 product with a promoter forming compound that en

hances the affinity of the resulting sugar uptake inhibi

tory compound of the invention for the surface mem
logical ef?cacies. A method for the manufacture of
brane of the small intestine.
these compounds is also provided.
The matrix is a polysaccharide with monomeric units
A further object of the invention is to provide certain 40 ranging from 150-500. The individual monomers may
phloretin and phlorizin derivative containing com
include glucose, mannose, galactose or any mixtures of
pounds that act as specific inhibitors of glucose absorp
these. The monomers may also carry appropriate func
tion from the intestine.
tional groups on either the free primary hydroxyl or the
An additional object of the present invention is to
free secondary hydroxyls. Functional groups include

provide new phloretin and phlorizin derivative contain= 45 carboxymethyl (—O-—CH2—CO2H), 2-hydroxy-3
ing compounds that are clinically safe and useful to
bromopropyl (—O--CH2—CHOH-CH2Br), amino
selectively inhibit glucose absorption from the intestine.
propyl-diethoxysilane
(—-Si(OC;>_H5)2—C3H6NH2),
A still further object of the invention is to provide
amine (—NH;), and amide (—NH--CO—CH3). Prefer
certain phloretin and phlorizin derivative containing
ably, the matrix is of high molecular weight of from
compounds and methods for their use in the manage 50 25,000 to 90,000 daltons with even higher values possi
ment and treatment of sugar transport disorders.
ble. Speci?c examples of matrices include carboxy
Another object of the present invention is to provide
methylcellulose; sodium carboxymethylcellulose; a car
novel phloretin and phlorizin derivative containing
boxymethyl derivative of a galactomannan from the
compounds and pharmaceutical compositions for inhib
guar plant (available as Jaguar CMG; from Celanese
iting sugar absorption from the intestinal tract.
55 Corporation); a dextran, such as BHP-activated Dex
A still further object of the invention is to provide
tran 70 (available from Pharmacia Fine Chemicals,
phloretin and phlorizin derivative containing com
Uppsula, Sweden); CH-Sepharose (available from Phar

pounds, pharmaceutical compositions and methods for

macia Fine Chemicals); and a N-hydroxysuccinimide

their use in the treatment of diabetes, obesity and dump

activated ester of a derivatized cross-linked agarose gel

ing syndrome.
Other objects and advantages of the present invention
will become apparent as the description thereof pro
ceeds.

60 bead support, such as Af?gel 15 (available from Biorad

Laboratories).

The leash forming compounds are coupled via amide
linkages with the functional groups of the matrix. The

In satisfaction of the foregoing objects and advan
leashes or spacer arms formed serve to hold the later
tages, there is provided by this invention compounds of 65 coupled inhibitory phloretin or phlorizin derivatives

pharmacological ef?cacy including phloretin and/or
phlorizin moieties formed from an intermediate deriva
tive selected from those of the following formulae:

away from the backbone of the matrix for reaction with
the sugar transporter of the intestinal membrane. For

example, the leash forming compounds couple to

4,760,135
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-

0—l0O% of the carboxy groups of a sodium carboxy

methylcellulose matrix. Speci?c leash forming com

pounds include glycine; N,N-diaminopropylmethyla
mine; tartaric acid; glutardialdehyde; and amino acids
with the formula NH2—(CHOH),,—CO2H, wherein
n: 1-6.

'

The intermediate phloretin or phlorizin derivative is

then coupled to the ?rst intermediate product formed
by coupling the leash forming compound with the ma
trix. The coupling is through the amine moiety of the 5’
C of a phlorizin intermediate compound or the 3’ C of a

phloretin intermediate compound. The amine moieties
bind remaining unbound functional groups of the matrix
and the distal ends of the leash forming compounds via
amide linkages that are resistant to the proteolytic en
zymes of the digestive tract.
The resulting second intermediate product is then
coupled with a promoter forming compound. Promoter

forming compounds include ethylenediamine and etha
nolamine. The promoter forming compound couples to

6

ethanol. The solutions are then mixed together and
brought to a pH of substantially 5.8 with the ethanol

level of the mixed solutions being approximately 15%.
Following the adding of a catalyst to promote the for
mation of the second intermediate product, the pH and
ethanol concentration are maintained at these levels.

The resulting second intermediate product is then puri

?ed by chromatography.
The third coupling step includes the steps of forming
a solution of the second intermediate product and pro
moter forming compound and adding a catalyst to this
solution to promote the coupling. The resulting reaction

product is then puri?ed by chromatography.
In each coupling step, the added catalyst is l-ethyl-3

(3-dimethylaminopropyl) carbodiimide (hereinafter
EDAC). This catalyst promotes coupling through
amide linkages as explained in Bodansky, M. and On

dett, M.S., Peptide Synthesis (Interscience, New York,

1966).

any remaining free functional groups of the matrix fol

DETAILED DESCRIPTION OF THE

lowing coupling of the matrix, leash forming compound

INVENTION
As indicated above, this invention relates to certain
innovative and novel compounds formed from coupling

and intermediate phloretin or phlorizin derivatives.

In an additional aspect of the present invention, in
accordance with its objects and purposes, sugar uptake 25 an intermediate phloretin or phlorizin derivative to an
inhibiting compositions are provided having as the ac
undigestible and non-absorbable matrix. The resultant
tive ingredient compounds as set forth above. Methods
compounds have pharmacological ef?cacies (1) since
are also provided for using these compositions in treat
the phloretin or phlorizin moiety acts as an inhibitor of
ing diabetes and dumping syndrome, as well as in pro
sugar uptake through a mechanism involving the sugar
moting weight loss. Each of these methods involves the 30 transporter of the intestine and (2) the undigestible and
administration to the patient of an effective dosage of
non-absorbable matrix prevents the phloretin or phlori

the sugar uptake inhibitory compounds of the invention.

The effective dosage is administered in the form of a

zin from entering the bloodstream and causing systemic,
toxic effects throughout the body tissues.

>

pharmaceutical preparation or composition wherein the
The phloretin derivatives used as intermediates in
inhibitory compound is admixed with a pharmaceutical 35 preparing the inhibitory compounds of the present in
organic or inorganic excipient. Suitable excipients are
vention are substituted in the 3’ C position by various
substances that do not react with the novel inhibitory

compounds. Speci?c examples of such excipients in
clude water, gum and starch. Of course, other known

primary amines. The phlorizin derivatives used as inter

mediates in preparing the inhibitory compounds of the
present invention are substituted in the 5' C positon also

medicinal excipients may be used. The compositions
may be designed to be taken orally in tablet or capsule
form. Preferably, the compositions are administered in

tution resulting in the formation of phloretin-3'-benzyla

an enteric-coated form to protect the amide linkages

mine, 4'-deoxyphlorizin-5’-benzylamine and phlorizin

connecting the various ligands with the non-digestible

with primary amines. Benzylamine is just one example
of an appropriate amine that may be used for this substi

5'-benzylamine.

matrix from the acidic environment of the stomach.
45
Substitution of a primary amine in the positions indi
In another aspect of the invention, in accordance
cated assures that the critical structure and geometric
with its objects and purposes, a method for the prepara
con?guration of the phloretin and phlorizin moiety

tion of compounds effective in inhibiting sugar uptake
in the small intestine without harmful side effects is
provided. The method involves the steps of: (1) cou
pling a leash forming compound with an undigestible
and non-absorbable matrix to obtain a ?rst intermediate

product; (2) coupling the ?rst intermediate product
with an intermediate phloretin or phlorizin derivative to

obtain a second intermediate product; and (3) coupling
the second intermediate product with a promoter form

ing compound.

responsible for and essential to sugar transport inhibi
tory action are retained. Further, the free amino termi
nus of the primary amine provides the structure neces

sary for linking the inhibitor derivative to the undigest
ible and non-absorbable matrix via an amide linkage.
The amide linkages formed are resistant to the proteo
lytic enzymes of the digestive tract. For example, exo
peptidase enzymes require a terminal free amino acid
and none are present in the resulting compound of the
invention. Further, the internal amide bonds should not
be cleaved by endopeptidases since critical recognition

The initial coupling step includes the steps of mixing
the leash forming compound and matrix together in
moities, such as lysine and arginine, are not present. The
solution and adding a catalyst to promote the coupling 60 amide bonds are also unaffected by the mildly alkaline
and the formation of the ?rst intermediate product.
conditions of the small intestine. Thus, the compounds
During the reaction, the pH of the solution is main
of the present invention pass through the intestine in
tained at substantially 5.8. The resulting ?rst intermedi
tact, thereby eliminating the toxic and systemic side
“A ate product is then puri?ed by dialyzing.
effects associated with unbound phloretin and phlorizin
The second coupling step includes the steps of dis 65 as known in the art.
solving the ?rst intermediate product, for example, a
The compounds of the present invention are formed
glycine-carboxymethylcellulose matrix, in water and
by serially coupling an undigestible and non-absorbable
the intermediate phloretin or phlorizin derivative in

matrix with a leash forming compound, an active inter

7
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trix compound should provide for 0-100% coupling of

mediate phloretin or phlorizin derivative and a pro
moter forming compound. The matrix is a polysaccha
ride having 150-500 monomeric units of glucose, man

the leash forming compound to the functional groups of
the matrix The leash forming compound serves to

nose, and/or galactose. Appropriate functional groups

project from the backbone of the matrix and provide a
site for attachment of the inhibitor moiety allowing free

are provided on the free primary hydroxyl or free sec
ondary hydroxyls of the monomers as coupling sites.

interaction between the inhibitor moiety and the trans

porter in the membrane. Glycine is the preferred leash
forming compound. It provides a stable “spacer arm”

Functional groups include carboxymethyl, 2-hydroxy

3-bromopropyl, aminopropyl-diethoxysilane, amine and

for attachment of the inhibitor moiety to the matrix.
amide. The matrix is of a high molecular weight of at
10 The amide bonds formed between the glycine and the
least 25,000—90,000 daltons.

Carboxymethylcellulose (CMC) is just one example

inhibitor derivative resist cleavage by the proteolytic

of an undigestible and non-absorbable matrix bearing
staple spacer arms of appropriate length so that each
attached inhibiting phloretin or phlorizin moiety is held
away from the polymeric backbone and free to interact
with and inhibit the glucose transporter in the intestinal
cell membrane. Sodium substituted carboxymethylcel
lulose (cellulose gum; available from Hercules, Inc.) is

enzymes of the digestive tract to retain the compound
of the present invention intact. Glycine also adds “?exi
bility” to the inhibitor moiety. Glycine forms a variety
of leash links due to the presence of dimers and trimers
of glycine. Thus, some of the inhibitor moieties should
always be a favorable distance from the brush border
membrane to readily react with the transporter of the

membrane surface. Examples of other leash forming

inexpensive and has stable —O—CH1CO2H groupings
that can easily be extended by glycine through which

20

compounds include N,N-diaminoproplymethylamine,

the inhibitor moiety may be attached. It also possesses a

tartaric acid, glutardialdehyde, and amino acids with

carbohydrate skeleton that is resistant to mammalian

the formula NH2—(CHOH)n—-CO2H, wherein n: 1-6.

The ?rst intermediate product resulting from the
coupling of the matrix to the leash forming compound is
solubility over the unsubstituted carboxymethylcellu
lose. This improved solubility aids in the method of 25 then coupled with the intermediate phloretin or phlori
zin primary amine derivative to form a second interme
producing the compounds of the present invention as
diate product. The coupling of the inhibitor moiety to
will be discussed below.
the ?rst intermediate product is through the amine
A carboxymethyl derivative of a galactomannan

amylases. Further, the sodium provides improved water

group so as to provide an amide linkage. Coupling of
the inhibitor moiety occurs at the ends of the leash
forming compounds on the matrix or to the functional

from the guar plant may also be used. It is a water-misci

ble gel having a molecular weight of about 220,000
daltons. It also is not digestible by the mammalian intes
tine.

groups of the matrix previously uncoupled by the leash
forming compound. Thus, inhibitor moieties of the

A small, water soluble cross-linked dextran having a

compound of the present invention are located at vary
ing distances from the matrix backbone so that some of
the inhibitor moieties are always located in the ideal

molecular weight of about 70,000 daltons may be used
as a matrix material. The dextran matrix has the advan—
tage of accessibility to the intestinal mucosa. Further, it
is available from Pharmacia Fine Chemicals in a

position for interacting with the transporter of the brush

bromohydroxypropyl activated form. The bromohy

border membrane.

droxypropyl groups react with primary amines, such as

the benzylamine moiety of the intermediate inhibitor

40

The compound resulting from serially coupling the
leash forming compound and intermediate inhibitory

thereby avoiding the formation of peptide linkages that

compound to the matrix may itself be used for inhibiting
sugar uptake in the treatment of diabetes, obesity and

may be cleaved by peptidases in the gut.

dumping syndrome. It should be recognized, however,

derivative to form stable secondary amine linkages,

that there may still remain free functional groups on the

CH-Sepharose could also be used as a matrix mate

rial. Advantageously, it offers a stable, hydrophobic

45 matrix such as carboxy groups that tend to make the

resulting compound highly anionic at neutral pH’s.
leash for spacing the inhibitor derivative from the ma
Since the brush border membrane is highly negatively
trix backbone so that it is more suitably located for
charged, repulsive forces may be present to prevent this
reaction with the sugar transporter of the brush border
compound from effectively interacting with the mem
membrane. While one peptide bond is required in the
linkage, it is formed with the aromatic amino group of 50 brane. In order to overcome this problem, it is preferred
to use the compound resulting from serially coupling
an inhibitor derivative such as phlorezin-5’-benzylamine
and, therefore, is highly unlikely to be cleaved by pepti

the leash and inhibitor moieties to the matrix as a second

dases.
A further example of a matrix material is a N-hydrox

intermediate product. The second intermediate product
is then coupled to a promoter forming compound." The
promoter forming compound couples to and covers up

ysuccinimide-activated ester of a derivatized cross 55

linked agarose gel bead support (such as Af?gel 15
available from Biorad Laboratories). Although it is
insoluble, it can be used to couple an amine containing
ligand, such as phlorezin-S'-benzylamine, spontaneously

any remaining free carboxy groups or other functional
groups on the matrix previously unreacted with the
leash forming compound or the intermediate inhibitor

derivative. Advantageously, the promoter forming

in aqueous solution. The matrix includes a l5-atom 60 compounds not only reduce or eliminate the polyan
ionic nature of the second intermediate product, but
spacer arm containing a cationic charge that advanta

they also enhance the af?nity of the resulting inhibitor
compound of the present invention for the membrane
surface by contributing positive charges to the com
mucosa. This serves to direct the inhibitor moiety
65 pound through their free amino termini. Speci?c exam
toward its site of action.
ples of promoter forming compounds include ethylene
A leash forming compound is coupled to the matrix

geously signi?cantly enhances its interaction with the
negatively charged outer sialoglyco-proteins of the

material to form a ?rst intermediate product. The molar

proportions of the leash forming compound to the ma

diamine and ethanolamine. Like the leash forming com
pounds and the intermediate inhibitor compounds cou

4,760,135

9

10

pled to the matrix, these promoter forming compounds

-continued

are linked via amide linkages that are resistant to cleav

age in the digestive tract.
In accordance with another aspect of the present
invention, the compounds may be utilized in a method

of treating diabetes. Particularly, the compounds of the
present invention inhibit sugar uptake and provide con

trol of post-prandial hyperglycemic episodes. Advanta

OH

OH

0§

Ho
HO

0

on

OH

geously, the compounds of the present invention do this
without toxic side effects and without inhibiting uptake

R1

of other essential nutrients.
The compounds may also safely be utilized in a

method to provide weight control. By selectively inhib
iting sugar uptake the compounds provide a reduction
in absorbed calories without the need of harsh dietary
discipline. By this, it is meant that a normal meal may be
ingested but it provides fewer absorbed calories just as
if food intake were reduced.

Additionally, the compounds may be utilized in a

@

0

R

wherein R is --OH or H and R1 is a primary amine
moiety; to an undigestible and non-absorbable matrix.
The method includes the initial step of coupling a
leash forming compound with the matrix to form a ?rst

intermediate product. The leash forming compound and
matrix are preferably dissolved in water but other ap-

method of treating dumping syndrome. Following a
gastrointestinal resection, food passes directly into the

20 propriate solvents may be used. The pH of the solutions

small intestine. This results in a very rapid increase of
sugar absorption into the bloodstream. The pancreas
then reacts by producing more insulin. The reaction

as, for example, by the addition of HCl as necessary.
EDAC catalyst is then added to the solution to promote

time is too slow, however, and the peak insulin level
occurs well after peak sugar levels. Thus, the blood

glucose drops rapidly rather than leveling off as would
normally occur. This results in hypoglycemia and, in

containing the compounds is then brought to about 5.8

the coupling through amide linkages. During the cou
pling the solution pH is maintained at substantially 5.8.
Following completion of the reaction, the solution con
taining the ?rst intermediate product is puri?ed. The
purifying step is performed by dialyzing the solution

severe cases, loss of consciousness. The compounds of 30 against water to remove the remaining catalyst, excess

the present invention avoid this problem by initially
inhibiting absorption of the sugar. Thus, the compounds
reduce or eliminate the very rapid increase of sugar

absorption, thereby reducing the high insulin require
ments of the individual and the degree of reaction of the

pancreas. Consequently, the compounds of the present

invention prevent the large ?uctuation in blood glucose

starting materials and any unwanted by-products of the
reaction.

The puri?ed ?rst intermediate product is then again
dissolved in water and the intermediate inhibitory
phloretin or phlorizin compound is dissolved in an ap

propriate solvent miscible with water, such as ethanol.

The solutions containing the ?rst intermediate product
levels typical of dumping syndrome and that often re
and intermediate inhibitory compound are then mixed
sult in loss of consciousness.
Preferably, compounds of the present invention are 40 together with the pH level brought to substantially 5.8
and the ethanol level brought to approximately 15%.
administered orally in tablet or capsule form. The tab
EDAC catalyst is added to the mixed solutions to pro
lets or capsules may include an enteric coating to pro
mote the formation of amide linkages between the inter
tect the compound from the acidic environment of the
mediate inhibitory compound and the ends of the
stomach. The tablets and capsules may include a com
position having compounds of the present invention, as 45 leashes and/or any unreacted functional groups of the
matrix. The EDAC catalyst promoted amide linkages
the active ingredient, admixed with excipients known in
between the inhibitory compound and the matrix are
the art. Thus, the tablet or capsule may contain a gum,
not cleaved by the enzymes of the gastrointestinal tract
starch, gelatin or even a buffer. The dosage for treat
and the phloretin/phlorizin moiety remains bound to
ment with the inhibitory compounds of the present
the matrix. Thus, the phloretin/phlorizin moiety does

invention depends on such factors as the age, weight
and condition of the individual patient as well as the

not enter the bloodstream and elicit toxic effects on

condition being treated. The compound should be ad

other organs of the body.

ministered before meals if maximum effect is to be ob

tained.
In accordance with still another aspect of the inven
tion methods for making the inhibitory compounds are
provided. The methods include coupling a primary
amine derivative of phloretin or phlorizin in accordance
with one of the following formulae:
R1
OH

OH
and

Following chromatographic puri?cation, the result
ing second intermediate product may be utilized in a

method of treating individuals where inhibiting sugar
uptake is desired. It is preferred, however, to couple the
second intermediate product to a promoter forming
compound so as to increase the af?nity of the inhibitor

product of the present invention for the mammalian
brush border membrane. This is done by preparing a

solution of the second intermediate product and the
promoter forming compound. The pH of this solution is
brought to substantially 5.8 and EDAC catalyst is
65 added to promote the coupling.

The following examples are presented to illustrate the
OH

invention but it is not to be considered as limited

thereto.
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the monohydrate. After drying at 80° C. in vacuo its
m.p. was: 215° C. after softening at 149° C.

EXAMPLE 1

Phlorizin (7 mmol) and p-nitrobenzaldehyde (5
mmol) were dissolved in 84 ml methanol and cooled to
0° C. Under a nitrogen atmosphere, 14 meq of l N KOH

were added dropwise with magnetic stirring and the

Elemental Analysis:

C

H

N

reaction was allowed to incubate for 2 hr at 0° C. and
then 1.5 hr at 50° C. The reaction mixture was recooled

Calculated for C30H33O11N:

61.64

5.69

2.49

to 0° C. and neutralized by the dropwise addition of 14

Found for acetamide derivative

61.58

5.90

2.32

meq of 0.5 N HCl. The solvent was removed in vacuo

of the reaction product:

to yield a brown syrup containing primarily the pre
sumed carbinol (carbinol was not suf?ciently stable to

The structure proposed for compound phlorizin-5’
benzylamine was con?rmed by comparing its proton
NMR spectra with that of phlorizin. The AZBZ pattern

be analyzed) and unreacted phlorizin. The mixture was
dissolved in 10 ml CHC13/CH3OH (4:1) and subjected
to flash chromatography on a column of Silica Gel 60

(4.5 X26 cm) that had been pressure packed with chlo

at 2.88 and 3.50 ppm arising from the —CH2CH2.
CO-moiety in phlorizin also appears at 2.87 and 3.49

roform. Elution was conducted with 0.75 L 15% metha

nol in chloroform, followed by 0.5 L 18% and then 0.5
L 22% of the same solvent mixture. Thin layer chroma
tography was used to monitor the fractionation: the
eluate volume between 0.4-0.5 L contained essentially

ppm in the spectra of phlorizin-5'-benzylamine (in both
compounds the triplet at 3.5 ppm is partially obscured

pure 2'-O-B-D-glucopyranosyl)-5'-p-nitrobenzyl carbi
nol (herinafter called GNC) (0.8 g, 20%) while the
0.5-1.4 L eluate contained 2.4 g of a mixture of GNC

contaminated with approximately 20% phlorizin. Rf 25

by the signals arising from the protons in the glucose
moiety). The B-ring AA'BB’-system at 6.72 and 7.10
ppm remained unchanged, but phlorizin’s A-ring AB

value of the presumed carbinol GNC in 25%

system at 5.99 and 6.25 ppm was converted to a l H

Me0H/CHCl3 was 0.25.

singlet at 7.42 ppm in compound phlorizin-5’-benzyla
Compound GNC (0.96 g in 100 ml methanol) was
catalytically hydrogenated with 150 mg 10% Pd on 30 mine. The new C ring AA'BB' system in compound
charcoal for 1 hr at 22° C. at atmospheric pressure, and
phlorizin-S'benzylamine gave signals at 6.54 and 6.98
then 3 hr at 55° C. at 30 cm H2O pressure. At lower
ppm
and the new -—CH2 group is seen as a 2H singlet at
temperatures reduction was incomplete and yielded an
unstable orange product. The catalyst was removed and
3.72 ppm. The reaction is schematically shown below.
the methanol was evaporated in vacuo to yield crude

phlorizin-5'-benzylamine (0.84 g, 92%) The product
was dissolved in 8 ml methanol and mixed with 10 ml

Sephadex G-l0 slurry equilibrated in 50% methanol.
Finally 8 ml H2O was added and the resulting slurry
was added to the top of a Sephadex G-10 column

no

(2.5 X27 cm) likewise equilibrated in 50% methanol.

0T
0

Elution was conducted with 0.8 L 50% methanol fol~

H0 H0

0

OH

lowed by 0.7 L 55% methanol and 1.0 L 60% methanol.
The amine was eluted in the 1.1-2.0 L fraction. If the

amine had been contaminated prior to this chromatog-:
raphy, phlorizin was readily separated at this step and

OH

could be recovered in the 0.36-0.66 L fraction. Phlori

zin-5’-benzylamine was obtained by evaporating the

the monohydrate (0.55 g, 60%); after drying at 80° C. in

KOH/MeOH

PHLORIZIN

solvent and crystallization from aqueous methanol as

pNOz/CéHSCHO

50

vacuo its m.p. was 197°-200° C.
Elemental Analysis:
Calculated for CZ8H3[O1QN.H2OZ
Found for the reaction product:

on

C

H

N

60.10
60.30

5.94
5.90

2.54
2.51

0%
O

OH

GLC/

I

In order to verify that the reaction conditions were

suf?cient to reduce the secondary hydroxyl group of

GNC, the phlorizin-5'~benzylamine reaction product

zylamine (97.8%).
An acetamide derivative of the reaction product pre
pared by coupling acetic acid and the amine in methanol
with EDAC, was crystallized from 30% methanol as

on on
t" @

60

was quantitatively acetylated with acetic anhydride in
the presence of pyridine. Theoretical incorporation is 8
moles acetate/mole glycoside. Found for phlorizin-5’
benzylamine: 7.82 moles acetate/mole phlorizin-5'-ben

GNC

Hz/Pd/C
55" c.

65

HN02/NaN3\L

HOAC/EDAC
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tion. Speci?cally, the radioactive glycinated-cellulose
product (?rst intermediate product of the overall syn

OH

PHLORIZlN-5’-

GLC/

thesis) was separated from excess starting materials,
by-products and catalyst using a Sephadex G-25 col
umn. Void volumes (determined with Blue Dextran)
and approximate column volumes were 11 ml and 22 ml,

o%
0

01-1

respectively. Aliquots of reactions I-VI from Table l
CH

were applied and eluted with water. Then one ml frac
tions were collected and assayed for I4C.
As shown in FIG. 1, the small Sephadex column

R

on
BENZYLAMINE
(X) R = _NH3

no
0
GLC = HO

14

glycinated cellulose was assessed by Sephadex gel ?ltra

-continued

15

HO

readily separated the 90,000 dalton glycinated-cellulose
product from the low molecular weight unreacted gly
cine and other products (dimers and trimers, etc. of
glycine) that enter the beads and were eluted only after
a column volume of water. The results of these tests,

OH

summarized in Table 1, indicate that:

This example demonstrates the synthesis of an inter

(1) high molar ratios of glycine and EDAC catalyst
relative
to the equivalents of available CMC-carboxyl
moiety on the 5’C. The synthesis of an intermediate 20 groups prevent coupling (see reactions V and VI); ap
mediate phlorizin derivative having a primary amine

phloretin derivative having an primary amine moiety on
the 3’C is set forth in “Phloretinyl-3'-benzylazide: A

High Af?nity, Probe for the Sugar Transporter in
Human Erythrocytes”, Fannin, F. F., Evans, J. 0.,
Gibbs, E. M., Deidrich, D. F., Biochemica et Bio

parently the excess glycine -—CO2H’s compete with
those on the CMC such that only glycylglycine and
25

physica Acta, 649 (1981) 189-201.

higher oligomers are formed; and
(2) the lower pH of 5.8 improves yield and when
molar ratios of CMC-—CO2H: glycine: catalyst are
l:l0:3, over 80% coupling occurs.

EXAMPLE 2

EXAMPLE 3

Sodium carboxymethylcellulose (CMC) (0.0625 gm;

To the dialyzed ?rst intermediate product of Exam
ple 2 was added 190 mg of radioactive phlorizin-S-ben

0.213 mmoles of —COZH groups i.e. 70% of anhydro
glucose units carry carboxymethyl groups) was dis
solved in 9 ml of water. To this solution was added 1 ml

zylamine (0.35 mmoles; l00p.Ci3H) in ethanol from

ing materials, by-products and spent catalyst from the

N NaOH to dissolve the product. This solution was

Example 1. Solid EDAC catalyst (100 mg; 0.52 mmoles)
aqueous solution of 80 mg radioactive glycine (1.066
was
then added to the solution and the reaction was
mmoles; l.2p.Cil4C). The solution was made to a pH of
5.8 with 0.2 N HCl. Then 123 mg of solid EDAC was 35 allowed to proceed for six hours. During this time the
ethanol level of the solution was maintained at 15%, the
added with stirring. As successful coupling reactions
temperature of the solution at 35°-40° C. and the pH
consumed hydrogen ions, the pH was maintained at 5.8
was maintained at 5.8. The reaction yielded a white
by the addition of 0.2 N HCl as required.
product (CMC-glycine-phlorizin-S'-benzylamine) as a
The resultant reaction mixture was then dialyzed
suspension with 20% of the -CO2H groups coupled
against 1 liter of water for 7 hours using a Spectrapor
with the amine derivative of phlorizin.
dialysis membrane (MW cutoff 6,000~8,000 daltons).
To 6.5 ml of the suspension was added l50p.L of 0.5
This was done as it is important to remove excess start
then chromatographed on a Sephadex G-25 column
?rst reaction in order to perform the next coupling step
in the overall synthesis set forth in Example 3 below. 45 (void volume 180-190 ml; hold up volume, 275 ml) with
A number of other test reactions were performed to

water as eluant. The second intermediate product,

ascertain the optimal reaction conditions that yield the
greatest coupling of CMC and glycine.

CMC-glycine-phlorizin-S'-benzylamine, was eluted in
25 ml at about the void volume. The second intermedi
ate product was completely separated from unreacted

TABLE 1
EXTENT OF REACTION:
MOLAR RATIOS OF

@@E
Rxn I-pH 5.8
1:5:3

to CMC carboxyl groups
total mMoles of available,
reactive carboxyl groups
82%

Rxn Il-pH 5.8
1:10:15

Rxn Ill-pH 6.8

50

55

*

35%

55%

121023

Rxn V-pl-l 4.8

0%

1:10002100
RXl'l VI-pl-l 6

0%

1210002100

CMC—-[14C] glycine and the [3H] phlorizin-5'-benzyla
mine. The amount of CMC-reactive groups recovered
in the water elution (92%, as determined from the [14C]
CPM applied) was compared to the phlorizin-5’-ben
zylamine present in these same fractions (as measured

87%

15:3

Rxn lV-pl-I 6.8

3H-phlorizon-5'-benzylamine because that starting ma
terial is tightly absorbed to the Sephadex G-25 and
requires ethanol to be eluted.
Aliquots of the fractionated reaction product were
used to determine the extent of binding between the

mMoles of Glycine coupled

60

by the bound [3H] CPM).
Aliquots of the Sephadex G-25 puri?ed second inter
mediate product were also examined with a TNBS

assay (see Antoni, G., Presentini, R. and Neri, P., Anal.
Biochem. 129 (1983) 6063). The reagent 2,4,6-trinitro
65 benzene sulfonic acid forms a yellow color with free

The pH of the reaction as well as the molar ratios of the

materials (CMC-matrix carboxyl groups: glycine li
gand; EDAC catalyst) were varied. The % yield of

primary amine groups that is measured spectrophoto
metrically. The results of the analysis indicate that the
G-25 puri?ed product contained only trace amounts of

15
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compounds in treating diabetics, the obese and gastroin

free amino groups. Therefore, from 87-100% of the
phlorizin-5'-benzylamine is coupled to the matrix
through the amino group. Had the ligand been coupled
in reverse fashion as, for example, through its phenol
groups, free amino groups could have been detected.
An awareness of the mode of coupling is crucial since

ence to certain preferred embodiments. However, as
obvious variations thereon will become apparent to
those skilled in the art, the invention is not to be consid

phlorizin possesses sugar transport inhibitory properties

ered as limited thereto.

testinal resection patients are disclosed.
The invention has been described herein with refer

We claim:

only when the phenolic groups are free to react with the

cell membrane surface. Thus, the phlorizin moieties

1. A compound, consisting of: a reaction product

bound to the cellulose matrix in this preparation are in

formed by serially coupling (1) an undigestible and

optimal con?guration for interaction with the intestinal
sugar transport system.
Further experimentation has shown that the pre
ferred molar ratio of glycinated CMC to phlorizin-5’
benzylamine to EDAC catalyst is 1:0.2:0.75. While
larger amounts of phlorizin-5’-benzylamine may be

non-absorbable polysaccharide matrix with a leash
forming compound selected from a group consisting of

glycine, N-N-diaminopropylmethylarnine, tartaric acid,
glutardialdehyde
and
NH2—(CHOH),,—COZH
wherein n: l-6 by dissolving the leash forming com
pound and matrix together in a solvent maintained at a

pH of substantially 5.8 and then adding l-ethyl-3-(3

readily incorporated into the product, such incorpora

dimethylaminopropyl) carbodiimide
to promote coupling and obtain a
the ef?ciency of the following reaction step and the 20 product; (2) said ?rst intermediate
intermediate inhibitory compound
pharmacological activity of the completed compound.

tion results in a loss of water solubility. The loss of
water solubility is to be avoided as it adversely effects

HCl as a catalyst
?rst intermediate

product with an
selected from a

group consisting of compounds having the following

EXAMPLE 4
To a 9 ml aliquot of the eluted solution of Example 3

containing the second intermediate product (CMC-gly

structures:
25

cine-phlorizin-S'-benzylamine) (containing approxi

R!
R

mately 2 mmoles of underivatized —CO2H groups) was
added 125 uL of a solution containing 10.6 mmoles of
ethanolamine hydrochloride. The pH of the solution 30
was brought to 5.8 and 2 mg. of solid EDAC catalyst
was added. The addition of the catalyst resulted in a

OH

OH
and

II
OH

O

rapid increase in pH signifying the coupling of the

OH

amine to the matrix. Within 1 hour the pH decreased to

about 5 signifying near completion of the reaction. The
mixture was then maintained at 4 C overnight. The ?nal

OH

product was puri?ed by chromatography on a Sepha
dex G-25 column. Eighty-eight percent of the radiola

O
HO
HO

beled product was recovered and it possessed the ex

O%
0

OH

OH

pected l‘lC/3H ratio of 0.018.
R1

EXAMPLE 5

An animal study was then conducted to determine

whether bacterial and other digestive action would split
the inhibitory compound of the present invention,
thereby leading to the absorption of toxic fragments.
The radioactive labeled compound of Example 4 (0.3

/].L Ci 3H labeled phlorizin moiety; 0.04;.tCi14C labeled

wherein R=-—OH or —H and R1 is a primary amine of
45

from l-lO carbon atoms effective in inhibiting glucose

uptake by dissolving said ?rst intermediate product and
said intermediate inhibitory compound in solvents, mix
ing the solvents, and adding l~ethyl-3-(3-dime

CMC) was inserted into the bowels of a single rat that
thylaminopropyl) carbodiimide HCl as a catalyst to
possessed a cecal ?stula. No radioactivity was found in 50 promote coupling while maintaining the pH of the
the blood plasma one or six hours after administration.
mixed solvents at substantially 5.8 so as to form a second
Furthermore, the radioactive material recovered from
intermediate product; and (3) said second intermediate
the bowel contents contained a 3H/14C ratio equal to
product with a promoter forming compound selected
that of the original material. Thus, fragmentation and
from a group consisting of ethylenediamine and etha

selective absorption or disposal of either labeled frag
ment did not occur.

nolamine by dissolving said promoter forming com
pound and said second intermediate product in solvent

In summary, numerous bene?ts have been described
maintained at a pH of substantially 5.8 and adding 1
which result from employing the concepts of the pres
ethyl-3=(3-dimethylaminopropyl) carbodiimide HCl as a
ent invention. A novel intermediate compound having
catalyst.
potential pharmacological ef?cacies is disclosed. Com 60 2. The compound of claim 1, wherein R1 includes an
pounds having selective sugar transport inhibitory ac
aromatic ring.
tion are also disclosed. These compounds include an
3. The compound of claim 1, wherein said intermedi
amino derivative of phloretin or phlorizin bound
ate inhibitory compound is phlorizin-5’-benzylamine.
through an amide linkage to an undigestible and non
4. The compound of claim 1, wherein said intermedi
absorbable matrix. Thus, the compounds avoid the
ate inhibitory compound is 4'-deoxyphlorizin-5’-ben

known systemic effects of phlorizin and phloretin while
advantageously providing their speci?c inhibitory ac

zylamine.

tion. Further methods for utilizing the chemically safe

ate inhibitory compound is phloretin-3'-benzylamine.

5. The compound of claim 1, wherein said intermedi

4,760,135
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6. The compound of claim 1, wherein said polysac
charide matrix has a molecular weight of from

25,000—90,000 daltons.
7. The compound of claim 1, wherein said polysac
charide matrix includes substantially 150-500 mono
meric units selected from a group consisting of

18

selected from a group consisting of compounds having
the following structures:
R1

LII
R

OH

OH
and

CH0

CH0
R

CH0

R

R

10

R

R

H

OH

O

R

and

OH

and

R

R

R

R

R

OH

R

O§

O

CHZR

and

any mixtures

CHZR

thereof,

HO
HO

CHZR

wherein

O

OH

on

R=—OH,
R1

20
R

8. The compound of claim 1, wherein said matrix is

wherein R=—OH or -—H and R1 is a primary amine of

carboxymethylcellulose.

from l-lO carbon atoms by dissolving said ?rst interme
9. The compound of claim 1, wherein said matrix is 25 diate product and said intermediate inhibitory com

sodium carboxymethylcellulose.

pound in solvents, mixing the solvents, and adding 1

10. The compound of claim 1, wherein said matrix is
a carboxymethyl derivative of a galactomannan from

ethyl-3-(3-dimethylaminopropyl) carboddimide HCl as
a catalyst to promote coupling while maintaining the
the guar plant.
11. The compound of claim 1, wherein said matrix is 30 pH of the mixed solvents at substantially 5,8.
15. The compound of claim 14, wherein said polysac
a water soluble cross-linked dextran of substantially
charide matrix includes monomeric units selected from
70,000 daltons.
a group consisting of
12. The compound of claim 1, wherein said matrix is

CH-Sepharose.
13. The compound of claim 1, wherein said matrix is 35

CH0

CH0

CH0

an N-hydroxysuccinimide-activated ester of a deriva

tized cross-linked agarose gel bead support.
14. A compound effective in inhibiting glucose up

R
R

take in a mammalian intestine, consisting of: a reaction

product formed by serially coupling (1) a polysaccha

R

40

ride matrix with a leash forming compound selected
from a group consisting of glycine, N-N-diamino

R

R

and

and

R

R

R

R

R
R

propylmethylamine, tartaric acid, glutardialdehyde and
NH2—(CHOH),,——CO2H wherein n: l-6 by dissolving
the leash forming compound and matrix together in a
solvent maintained at a pH of substantially 5.8 and then

CHZR

CHgR

CHZR

45

adding l-ethyl-3-(3-dirnethylaminopropyl) carbodiim
ide HCl as a catalyst to promote coupling and obtain a

first intermediate product and (2) said ?rst intermediate
product with an intermediate inhibitory compound 50

55

65
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